Addex receives nasdaq notification regarding minimum bid price deficiency

Ad hoc announcement pursuant to art.   53 lr   geneva, switzerland, may 1 8 , 202 2 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the company), announced today that it had received written notification from nasdaq indicating that, for the last thirty consecutive business days, the bid price for the company's american depositary shares (adss) had closed below the minimum us$1.00 per ads requirement for continued listing on nasdaq under listing rule 5550(a)(2).
ADXN Ratings Summary
ADXN Quant Ranking